MSN: Researchers study how immunotherapy affects COVID-19 outcomes
MSN highlighted recent research from the University of Cincinnati Cancer Center on how immunotherapy treatments and immunosuppression affects the severity of COVID-19 infections for patients with cancer.
Trisha Wise-Draper, MD, PhD, co-led the research that was recently published in JAMA Oncology.
"We reviewed patients with cancer, those that had baseline immunosuppression, and those that were treated with immunotherapy prior to getting COVID-19," said Wise-Draper, associate professor of medicine in the Division of Hematology/Oncology, section head for Medical Oncology in UC’s College of Medicine, Head and Neck Center of Excellence co-leader and a UC Health physician. "The most important finding is that although those treated with immunotherapy alone did not have an effect on COVID-19 disease outcomes, those that had baseline immunosuppression and were treated with immunotherapy had worse outcomes with COVID-19."
Related Stories
DAAP appoints Joseph Heathcott as new associate dean for research
August 27, 2026
DAAP appoints new associate dean for research Joseph Heathcott, who will bring a nationally recognized voice in urban development, design and research to the University of Cincinnati starting this fall 2026.
One in four NFL players had CTE at death
August 25, 2026
Forbes cites research on concussions and football helmets by the University of Cincinnati in a report that found one in four NFL players had brain damage at death.
How UC's co-op model can benefit small businesses
August 25, 2026
The Business of Home recently dove into how a Chicago-based interior design firm benefits from UC's co-op model.